NCT03132584 2019-01-14
Cyclophosphamide and Alemtuzumab In Lymphoma
Dana-Farber Cancer Institute
Phase 1 Terminated
Clinical Trials
5 trialsNCT00637390 2016-12-02
A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.
University of Michigan Rogel Cancer Center
Phase 1 Terminated
NCT00943293 2014-03-17
Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
University of Chicago
Phase 1 Terminated
NCT00113048 2014-02-05
Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies
Sanofi
Phase 1 Terminated
NCT00947388 2013-08-22
Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
Case Comprehensive Cancer Center
Phase 1 Terminated